Latest Shenzhen Chipscreen Biosciences Ltd. Stories
SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009, in Orlando, Florida. Chidamide/HBI-8000 is a novel benzamide class histone deacetylase...
- Boughs or branches.
- Warbling of birds in trees.